cefuroxime and 7432 s
cefuroxime has been researched along with 7432 s in 17 studies
Research
Studies (17)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 5 (29.41) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bragman, SG; Casewell, MW | 1 |
| Barry, AL; Jones, RN | 1 |
| Edlund, C; Nord, CE; Stark, C | 1 |
| Rodriguez, WJ; Wiedermann, BL | 1 |
| Verbist, L; Verhaegen, J | 1 |
| Dvoretskiĭ, LI; Iakovlev, SV; Shakhova, TV; Suvorova, MP | 1 |
| Docheva, Iu; Ergova, R; K'oleian, E; Kharalambieva, Ia; Mitov, I | 1 |
| Banke, S; Bergman, B; Boman, H; Cronberg, S; Eilard, T; Elbel, E; Hugo-Persson, M; Johansson, E; Kuylenstierna, N; Lanbeck, P; Lindblom, A; Paulsen, O; Schönbeck, C; Walder, M; Wieslander, P | 1 |
| Kamanin, EI; Kozlov, SN; Otvagin, IV; Strachunskiĭ, LS | 1 |
| Amores, R; Calvo, A; Prieto, J; Sevillano, D; Valero, E | 1 |
| Ahel, V; Averchenkova, L; Palcevski, G; Ratchina, S; Rosovic-Bazijanac, V; Vlahović-Palcevski, V | 1 |
| Bedenic, B; Bubonja, M; Budimir, A; Topic, M | 1 |
| Brandsch, M; Luckner, P | 1 |
| Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Reviews
2 review(s) available for cefuroxime and 7432 s
| Article | Year |
|---|---|
The role of newer oral cephalosporins, fluoroquinolones, and macrolides in the treatment of pediatric infections.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Infections; Cefixime; Cefotaxime; Cefpodoxime Proxetil; Cefprozil; Ceftibuten; Ceftizoxime; Cefuroxime; Cephalosporins; Child; Clarithromycin; Fluoroquinolones; Humans | 1994 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Trials
2 trial(s) available for cefuroxime and 7432 s
| Article | Year |
|---|---|
[Program of empirical antibacterial therapy of community-acquired pneumonia].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftibuten; Cefuroxime; Cephalosporins; Community-Acquired Infections; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Male; Middle Aged; Pefloxacin; Pneumonia, Bacterial; Roxithromycin; Spiramycin | 1998 |
Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftibuten; Cefuroxime; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Injections, Intravenous; Male; Middle Aged; Norfloxacin; Prospective Studies; Pyelonephritis; Recurrence; Treatment Outcome | 2001 |
Other Studies
13 other study(ies) available for cefuroxime and 7432 s
| Article | Year |
|---|---|
The in-vitro activity of ceftibuten against 475 clinical isolates of gram-negative bacilli, compared with cefuroxime and cefadroxil.
Topics: Bacterial Infections; Cefadroxil; Ceftibuten; Cefuroxime; Cephalosporins; Drug Resistance, Microbial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests | 1990 |
In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
Topics: Administration, Oral; Cefaclor; Cefixime; Cefotaxime; Ceftibuten; Cefuroxime; Cephalexin; Cephalosporins; Enterobacteriaceae; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Neisseria meningitidis; Streptococcus | 1988 |
The relationship between an increase in beta-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances.
Topics: Administration, Oral; Adult; Amoxicillin; beta-Lactamases; Cefpodoxime Proxetil; Ceftibuten; Ceftizoxime; Cefuroxime; Cephalosporins; Feces; Female; Humans; Intestines; Male; Middle Aged; Prodrugs | 1994 |
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefaclor; Cefadroxil; Cefatrizine; Cefepime; Cefixime; Cefotaxime; Cefpirome; Cefpodoxime; Ceftazidime; Ceftibuten; Ceftizoxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cephradine; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Piperacillin; Pneumococcal Infections; Serotyping; Species Specificity; Streptococcus pneumoniae | 1998 |
[A comparative study of antibacterial activity of ceftibuten, ceftazidime, cefuroxime and ampicillin against clinical isolates].
Topics: Ampicillin; beta-Lactamases; Ceftazidime; Ceftibuten; Cefuroxime; Cephalosporins; Drug Resistance, Microbial; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Penicillins; Respiratory Tract Infections; Sensitivity and Specificity | 2000 |
[Comparative clinical efficacy and tolerance of cefuroxime axetil (zinnat) and ceftibuten (cedex) in patients with acute sinusitis].
Topics: Acute Disease; Adult; Ceftibuten; Cefuroxime; Cephalosporins; Drug Tolerance; Female; Humans; Male; Sinusitis; Treatment Outcome | 2001 |
[Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae].
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Cefaclor; Cefixime; Cefpodoxime; Ceftibuten; Ceftizoxime; Cefuroxime; Cephalosporins; Clavulanic Acid; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Pneumonia, Pneumococcal; Spain; Streptococcus pneumoniae | 2001 |
Antibiotic use profile at paediatric clinics in two transitional countries.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; Azithromycin; Ceftibuten; Ceftriaxone; Cefuroxime; Cephalosporins; Child; Child, Preschool; Croatia; Data Collection; Developing Countries; Doxycycline; Drug Utilization Review; Gentamicins; Hospital Records; Hospitals, University; Humans; Infant; Leucomycins; Outpatient Clinics, Hospital; Pharmacoepidemiology; Retrospective Studies; Russia | 2004 |
Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model.
Topics: Acetamides; Administration, Oral; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; beta-Lactamases; Biomarkers; Cefadroxil; Ceftibuten; Cefuroxime; Cephalexin; Cephalosporins; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Linezolid; Middle Aged; Norfloxacin; Oxazolidinones; Time Factors; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2006 |
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Binding Sites; Caco-2 Cells; Dose-Response Relationship, Drug; Humans; Peptide Transporter 1; Protein Binding; Rats; Symporters | 2005 |
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Topics: Animals; beta-Lactams; Cell Line, Tumor; Dipeptides; Drug Design; Humans; Mammals; Models, Molecular; Oligopeptides; Peptide Transporter 1; Quantitative Structure-Activity Relationship; Substrate Specificity; Symporters | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |